An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2018
Price : $35 *
At a glance
- Drugs Sirolimus (Primary) ; Budesonide; Clobetasol; Dexamethasone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 24 Oct 2017 Status changed from recruiting to discontinued.
- 14 Oct 2014 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record.
- 02 Jul 2014 New trial record